If Verbio was on your watchlist instead of in your portfolio, the outcome over the past year may feel like a missed shot. For Verbio shareholders, the return over the past year was 59.1%, including dividends. That headline alone raises a tougher question. Back on 2025-11-06, could a focus on Verbio’s ambition to lift profit margins into the low teens on the back of advanced biofuels and new product lines reasonably flag that potential payoff?
The easy part of this move is behind Verbio. Zero in on 225 high quality undervalued stocks for companies trading below our estimates.
The shares cost €16 at the start of the period, and Verbio sat between two very different stories about what might happen next.
On the bullish side, one thesis pointed to a Fair Value of €30.28, a notional price implied by optimistic assumptions about the future. That view leaned on Verbio lifting its profit margin toward 11.0% and building on advanced biofuels, biomethane and new product lines.
The bearish script argued for a Fair Value of €9.8, again an inferred number based on far tougher expectations. In that scenario, rising regulation and feedstock costs were expected to keep profit margins nearer 5.2% and pressure Verbio’s core biofuel markets.
Verbio commissioning the Bitterfeld plant for bio based speciality chemicals supported the optimistic case that new product lines could widen margins beyond pure fuels. Quarterly figures pointed in the same direction. Revenue reached €531.935m and profit moved from a loss of €97.382m to earnings of €41.638m, lifting net margin from 22.5% to 7.8%. The evidence supported the optimistic case.
The key assumption here was margin potential, not just revenue growth. For another stock, you would track net margin and segment mix each year against any story about higher quality earnings rather than only watching the top line.
Verbio trades at €26.12 today, and the selected Narrative places its Fair Value above that level based on what current assets and quota exposure could support if present conditions hold.
The argument leans on execution. The Narrative contends today’s price still does not fully credit Verbio successfully converting integrated biorefineries and Bitterfeld into durable earnings and cash flow.
"The main factor that needs to work in Verbio’s favor is that it turns its integrated biorefinery and new Bitterfeld specialty chemicals capacity into sustained earnings and cash flow growth, while keeping capital spending disciplined."
One Narrative disagrees with today's price. → See where this Narrative says Verbio should trade
You may be late to this rally, but that does not have to mean arriving late to every opportunity. Start with companies whose prices leave room for a different view of their future. Here are three trading below our estimates.
Three companies from the same screener. Open every one of the 193 solid balance sheet companies →
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com